Abstract:Introduction The aim of this study was to investigate the association of donor CD4 + T cells expressing CD62L with transplant outcomes. Materials and Methods We report a prospective analysis of 31 patients who were treated with a Bu/Cy regimen, followed by unmanipulated blood and marrow transplantation. Results Median number (range) of CD4 + CD62L + , CD4 + CD45RA + CD62L + , and CD4 + CD45RO + CD62L + cells infused were 0.31(0.05–1.10)×10 8 /kg, 0.22(0.03–0.95)× 10 8 /kg, and 0.17(0.01–0.81)×10 8 /kg, respectively. The incidence of grades II to IV aGVHD was 36%. In a multivariate analysis, infusion of >0.22 × 10 8 CD4 + CD45RA + CD62L + cells infused/kg increased the risk of grades II to IV aGVHD (HR = 4.741, 95% CI = 1.037–21.662, P = 0.045). Thirteen of 31 patients experienced cGVHD, the risk of cGVHD was increased in patients receiving >0.45 × 10 8 CD4 + CD45RA + cells infused/kg (HR = 4.614, 95% CI = 1.265–16.829, P = 0.021). Conclusion Our results suggest that a high cell dose of CD4 + CD45RA + CD62L + cells increase the incidence of grades II–IV aGVHD. A high number of CD4 + CD45RA + cells infused were associated with increased risk of cGVHD in our transplant settings.

Expression of CD62L on Donor CD4 + T Cells in Allografts: Correlation with Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation